Ipratropiumbromid/Salbutamol "neutec" (Ipratropium Bromide, Salbutamol)

Ipratropium bromide blocks muscarinic receptors on airway smooth muscle, preventing acetylcholine‑induced constriction. Salbutamol activates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. The dual mechanism provides additive bronchodilation, improving airflow in obstructive airway conditions.

The prescribed dose of Ipratropiumbromid/Salbutamol "neutec" is determined by the treating clinician based on the patient’s disease severity, response, and overall treatment plan. Patients should follow the specific inhalation instructions provided by their healthcare professional.

Safety data for Ipratropiumbromid/Salbutamol "neutec" in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request a supply, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

When used separately, ipratropium provides anticholinergic bronchodilation while salbutamol offers β2‑adrenergic stimulation. The combination inhaler delivers both mechanisms simultaneously, often achieving faster and more complete airway opening than either agent alone, especially in patients who need dual pathway relief.

Store the inhaler at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct heat, and ensure the canister is upright when not in use to maintain dose consistency.

The device is a metered‑dose inhaler (MDI). After shaking the canister, the patient exhales fully, places the mouthpiece in the mouth, and actuates a puff while inhaling slowly and deeply. The prescribed number of puffs is then repeated, followed by a breath hold of a few seconds.

Serious adverse events include paradoxical bronchospasm, significant tachycardia or arrhythmia, angioedema, and severe hypertension. If any of these occur, the inhaler should be discontinued immediately and medical attention sought.

Patients with known hypersensitivity to ipratropium bromide, salbutamol, or any excipients in the formulation should avoid this product. Caution is also advised for individuals with narrow‑angle glaucoma, severe urinary retention, or uncontrolled cardiac arrhythmias, and the decision should be guided by a healthcare professional.